Table 1. Characteristics of Included Studies in Meta-analysis.
| Study, Year (Reference) | FIT Brand | Country | FIT Samples, n | Cutoff Value for a Positive Test Result, μg/g | Cohort Size, n | CRC Cases, n |
|---|---|---|---|---|---|---|
| Sohn et al, 2005 (14) | OC-Hemodia† | Korea | 1 | 20 | 3794 | 12 |
| Levi et al, 2011 (15) | OC-Micro | Israel | 3 | 14 | 1204 | 6 |
| Allison et al, 1996 (31) | HemeSelect† | United States | 3 | 100 | 7493 | 35 |
| Allison et al, 2007 (32) | FlexSure OBT | United States | 3 | 300 | 5356 | 14 |
| Levi et al, 2007 (33) | OC-Micro | Israel | 3 | 15 | 80 | 3 |
| Cheng et al, 2002 (34) | OC-Light | Taiwan | 1 | 10 | 7411 | 16 |
| Morikawa et al, 2005 (35) | MagStream HemSp | Japan | 1 | 67 | 21 805 | 79 |
| Nakama et al, 1999 (36) | Monohaem | Japan | 1 | 20 | 4611 | 18 |
| Nakama et al, 1996 (37) | Monohaem | Japan | 1 | 20 | 3365 | 12 |
| Launoy et al, 2005 (38) | MagStream HemSp | France | 2 | 67 | 7421 | 28 |
| Itoh et al, 1996 (39) | OC-Hemodia† | Japan | 1 | 10 | 27 860 | 89 |
| Nakazato et al, 2006 (40) | OC-Hemodia† | Japan | 2 | 16 | 3090 | 19 |
| Park et al, 2010 (41) | OC-Micro | Korea | 1 | 20 | 770 | 13 |
| de Wijkerslooth et al, 2012 (42) | OC-Micro | The Netherlands | 1 | 20 | 1256 | 8 |
| Parra-Blanco et al, 2010 (43) | OC-Light | Spain | 1 | 10 | 1756 | 14 |
| Chiu et al, 2013 (44) | OC-Light | Taiwan | 1 | 10 | 8822 | 13 |
| Chiang et al, 2011 (45) | OC-Light | Taiwan | 1 | 10 | 2796 | 28 |
| Brenner and Tao, 2013 (46) | OC-Micro | Germany | 1 | 6.1 | 2235 | 15 |
| Brenner and Tao, 2013 (46) | Ridascreen Haemoglobin | Germany | 1 | 24.5 | 2235 | 15 |
| Mean Age, y | Reference Standard* | Sensitivity (95% CI) | Specificity (95% CI) | Positive LR (95% CI) | Negative LR (95% CI) |
|---|---|---|---|---|---|
| 48.9 | Colonoscopy | 0.25 (0.05–0.57) | 0.99 (0.98–0.99) | 18.91 (6.83–52.33) | 0.76 (0.55–1.00) |
| 60.4 | 2-y follow-up | 1.00 (0.54–1.00) | 0.88 (0.86–0.90) | 7.59 (5.88–9.80) | 0.08 (0.01–1.00) |
| NR‡ | 2-y follow-up | 0.69 (0.50–0.84) | 0.94 (0.94–0.95) | 12.27 (9.54–15.78) | 0.33 (0.20–0.55) |
| 58.8 | 2-y follow-up | 0.86 (0.57–0.98) | 0.97 (0.96–0.97) | 28.44 (21.88–36.97) | 0.15 (0.04–0.53) |
| NR | Colonoscopy | 0.67 (0.09–0.99) | 0.83 (0.73–0.91) | 3.95 (1.54–10.12) | 0.40 (0.08–1.00) |
| 46.8 | Colonoscopy | 0.88 (0.62–0.98) | 0.91 (0.90–0.92) | 9.69 (7.94–11.82) | 0.14 (0.04–0.50) |
| 48.2 | Colonoscopy | 0.66 (0.54–0.76) | 0.95 (0.94–0.95) | 12.13 (10.25–14.35) | 0.36 (0.27–0.49) |
| NR | Colonoscopy | 0.56 (0.29–0.76) | 0.97 (0.96–0.97) | 16.68 (10.72–25.94) | 0.46 (0.27–0.77) |
| NR§ | 2-y follow-up | 0.83 (0.52–0.98) | 0.96 (0.95–0.96) | 19.01 (14.10–25.62) | 0.17 (0.05–0.62) |
| 61.3 | 2-y follow-up | 0.86 (0.67–0.96) | 0.94 (0.94–0.95) | 15.46 (12.94–18.48) | 0.15 (0.06–0.37) |
| 45.2 | 2-y follow-up | 0.87 (0.78–0.93) | 0.95 (0.95–0.95) | 17.00 (15.44–18.73) | 0.14 (0.08–0.24) |
| 53.4 | Colonoscopy | 0.53 (0.29–0.76) | 0.87 (0.86–0.88) | 4.10 (2.65–6.35) | 0.54 (0.34–0.87) |
| 59.3 | Colonoscopy | 0.77 (0.46–0.95) | 0.94 (0.92–0.95) | 12.13 (8.10–18.18) | 0.25 (0.09–0.66) |
| 60.0 | Colonoscopy | 0.75 (0.35–0.97) | 0.95 (0.93–0.96) | 14.40 (9.05–22.92) | 0.26 (0.08–0.88) |
| 62.7 | 2-y follow-up | 1.00 (0.77–1.00) | 0.93 (0.91–0.94) | 13.01 (10.75–15.74) | 0.04 (0.01–0.55) |
| 58.8 | Colonoscopy | 0.85 (0.54–0.97) | 0.92 (0.91–0.92) | 10.21 (8.02–13.01) | 0.17 (0.05–0.60) |
| 49.0 | Colonoscopy | 0.96 (0.82–1.00) | 0.87 (0.85–0.88) | 7.21 (6.41–8.12) | 0.04 (0.01–0.28) |
| 62.7 | Colonoscopy | 0.73 (0.45–0.92) | 0.96 (0.95–0.96) | 16.44 (11.46–23.59) | 0.28 (0.12–0.65) |
| 62.7 | Colonoscopy | 0.60 (0.32–0.84) | 0.95 (0.94–0.96) | 13.06 (8.29–20.57) | 0.42 (0.23–0.78) |
CRC = colorectal cancer; FIT = fecal immunochemical test; LR = likelihood ratio.
*
Either a colonoscopy (detects CRC and adenomas) or a 2-y longitudinal follow-up using a cancer registry (only detects CRC) was used for patients with negative FIT results.
†
Discontinued and no longer in production in the United States.
‡
Mean age >45 y because inclusion criteria for patients had to be ages >50 y.
§
Mean age >45 y because only 21% of their cohort participants were aged 40–49 y.